Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock (ECMO-CS) trial
The ECMO-CS trial was conducted to compare the effects of immediate implementation of VA-ECMO vs. an initially conservative therapy in patients with rapidly deteriorating or severe cardiogenic shock.
The primary endpoint was the composite of death from any cause, resuscitated circulatory arrest, and implementation of another mechanical circulatory support device at 30 days.
A total of 122 patients were randomized, and 117 subjects were included in the analysis after excluding 5 patients due to the absence of informed consent.
The composite primary endpoint occurred in 37 (63.8%) and 42 (71.2%) of patients in the immediate VA-ECMO and the no early VA-ECMO groups, respectively (hazard ratio, 0.72; 95% confidence intervals [CI], 0.46 to 1.12; P=0).
So the patient has got Low Cardiac index with low preload as evident by low SVI and high after load as evident by high SVRI &PVRI. the heart contractility is not great either as evident by the low LVSWI & RVSWI. All this should direct us to administering volume in the first instance as long as the PCWP is kept below 22 (or better if kept <20). If this was not sufficient then giving an inotropic agent (inodilator) would enhance contractility and reduce after load.